

REMARKS

Upon entry of the foregoing amendment, claims 1, 12, 13, 21, 24, 25, 29, 31 and 39-42, and new claims 43-60 are pending, with claim 18 newly canceled without prejudice to Applicants' right to pursue the canceled subject matter in one or more related continuation, divisional, or continuation applications.

Claims 1 and 12 are amended to delete the recitation of a mutation at amino acid position 48. Also, claim 1 is amended to delete the recitation that the mutation is not V32I since the mutation at amino acid 32 is no longer recited. Also, claim 1 is amended to delete the recitation that the mutation at 43 is T, since the mutation at amino acid 43 is no longer recited. The amendment of claim 1 is supported by claims 1 and 12 as originally filed and by the specification at page 15, lines 17-23.

Claim 42 is amended to delete the recitation that 9-19 of the mutations are detected as the detection of this number of mutations no longer has support in claim 1.

New claims 43-60 recite the detection of mutations in addition to the mutations recited in claim 1. The new claims find support in the claims as previously filed.

Accordingly, no new matter is added by the amendments to the claims.

The Rejection of the Claims Under 35 U.S.C. 102(b) Is Traversed or Rendered Moot

Claims 1, 12, 13, 18 21, 24, 25, 29, 31 and 39-42 stand rejected as anticipated by Palmer et al., 1999, AIDS 71:661-67 (hereinafter "Palmer"). Applicants believe that the rejection is now moot as the claims no longer recite mutations at amino acid 48. Also, Palmer does not teach or suggest that any of the codons presently recited by the claims are significantly associated with amprenavir resistance. Accordingly, Applicants respectfully request withdrawal of the rejections under 35 U.S.C. § 102.

CONCLUSION

In view of the foregoing amendment and remarks, each of the claims remaining in the application is in condition for immediate allowance. Accordingly, the Examiner is respectfully requested to reconsider and withdraw the outstanding rejections. The Examiner is respectfully invited to telephone the undersigned at (336) 747-7541 to discuss any questions relating to the application.

Respectfully submitted,

Date: January 15, 2010



Cynthia B. Rothschild (Reg. No. 47,040)

KILPATRICK STOCKTON LLP

1001 West Fourth Street
Winston-Salem, North Carolina 27101-2400
Phone: (336) 747-7541
Facsimile: (336) 607-7500